Loading
Latest filing published 02 Jul 2021 for Sigilon Therapeutics, Inc., €3,248. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Only one filing by Robert R. Ruffolo is known so far (2 July 2021): an option exercise, €3,248, in Sigilon Therapeutics, Inc. That is too little to draw conclusions. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration